# A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)

> **NCT04398953** · PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 102 (estimated)

## Conditions studied

- Relapsed / Refractory Mantle Cell Lymphoma (MCL)

## Interventions

- **DRUG:** TQ-B3525

## Key facts

- **NCT ID:** NCT04398953
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-20
- **Primary completion:** 2021-09
- **Final completion:** 2021-09
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2020-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04398953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04398953, "A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04398953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*